Factors associated with a placebo effect in Parkinson’s disease in clinical trials: a meta-analysis

Shotaro Haji, Wataru Sako, Yuishin Izumi

Objectives Outcomes of clinical trials of treatment in patients with Parkinson’s disease (PD) may be influenced by placebo effects. The aim of this study was to determine the factors associated with placebo effects in Parkinson’s disease (PD) for guidance with design of future clinical trials.

Methods Factors associated with placebo effects in PD were examined in a meta-analysis using a random effects model with pooling of placebo effects on the Unified Parkinson’s Disease Rating Scale part III (UPDRS III) or Movement Disorder Society sponsored revision of UPDRS III (MDS-UPDRS III). The following prespecified variables were included in the analyses: with or without drug at baseline, with or without a placebo run-in phase, with or without motor fluctuation, published year, number of study sites, placebo administration period, age, sex, disease duration, and daily levodopa dose. Publication bias was assessed by visual inspection of funnel plots and adjusted using the trim-and-fill method.

Results Thirty-eight articles with a total of 4828 subjects satisfied the inclusion criteria. There was a significant placebo effect using UPDRS III or MDS-UPDRS III (SMD=-0.25; 95% CI -0.35 to -0.14; p<0.001, I2=92%). Subgroup and/or multivariate meta-regression analyses revealed that placebo effects were associated with advanced PD (p=0.04), drug exposure at baseline (p<0.001), placebo administration period (p<0.001), and disease duration (p<0.01).

Conclusions The results of this study are important as guidance in design of future clinical trials in which the influence of placebo effects is minimized.

---